Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SYRE
stocks logo

SYRE

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.807
-0.34%
--
--
-0.656
+9.41%
--
--
-0.702
+43.24%
Estimates Revision
The market is revising No Change the revenue expectations for Spyre Therapeutics, Inc. (SYRE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 97.12%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-23.24%
In Past 3 Month
Stock Price
Go Up
up Image
+97.12%
In Past 3 Month
Wall Street analysts forecast SYRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SYRE is 54.00 USD with a low forecast of 43.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast SYRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SYRE is 54.00 USD with a low forecast of 43.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 33.510
sliders
Low
43.00
Averages
54.00
High
70.00
Current: 33.510
sliders
Low
43.00
Averages
54.00
High
70.00
Deutsche Bank
NULL
to
Buy
initiated
$43
2025-09-26
Reason
Deutsche Bank
Price Target
$43
2025-09-26
initiated
NULL
to
Buy
Reason
Deutsche Bank initiated coverage of Spyre Therapeutics with a Buy rating and $43 price target. The company's goal is to create improved biologic drugs for inflammatory bowel disease, such as ulcerative colitis and Crohn's disease, the analyst tells investors in a research note. The firm believes Spyre could become a leader in inflammatory bowel disease with its extended half-life antibodies and fixed-dose combo therapies. It sees a modest valuation at current share levels.
Leerink Partners
Faisal Khurshid
Buy
Initiates
$45
2025-04-08
Reason
Leerink Partners
Faisal Khurshid
Price Target
$45
2025-04-08
Initiates
Buy
Reason
Jones Trading
Debanjana Chatterjee
Hold
Initiates
n/a
2024-12-11
Reason
Jones Trading
Debanjana Chatterjee
Price Target
n/a
2024-12-11
Initiates
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Spyre Therapeutics Inc (SYRE.O) is -11.62, compared to its 5-year average forward P/E of -4.96. For a more detailed relative valuation and DCF analysis to assess Spyre Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.96
Current PE
-11.62
Overvalued PE
-1.83
Undervalued PE
-8.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.24
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.58
Undervalued EV/EBITDA
-5.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
592.58
Current PS
0.00
Overvalued PS
2607.42
Undervalued PS
-1422.26
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

SYRE News & Events

Events Timeline

(ET)
2025-12-01
10:00:00
Goldman Sachs Upgrades Chime to Buy with $27 Price Target
select
link
2025-11-04 (ET)
2025-11-04
16:42:33
Spyre Therapeutics Announces Q3 Earnings Per Share of 15 Cents, Below Consensus Estimate of 74 Cents
select
2025-10-13 (ET)
2025-10-13
21:16:53
Spyre Therapeutics Prices 14.86M Share Spot Secondary at $18.50
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
12-01Benzinga
Chevron Analyst Becomes Optimistic; Check Out the Top 5 Upgrades for Monday

  • Analyst Upgrades: Several Wall Street analysts have upgraded their ratings on various companies, including Neumora Therapeutics, Old Dominion Freight Line, Toast Inc, Chevron Corp, and Spyre Therapeutics.

  • Neumora Therapeutics: RBC Capital upgraded Neumora Therapeutics from Sector Perform to Outperform, raising the price target from $4 to $7, while shares closed at $2.24.

  • Old Dominion Freight Line: BMO Capital upgraded Old Dominion Freight Line from Market Perform to Outperform, lowering the price target from $172 to $170, with shares closing at $135.29.

  • Chevron Corp and Others: HSBC upgraded Chevron from Hold to Buy with a price target increase from $166 to $169, and other companies like Toast and Spyre Therapeutics also received positive upgrades from analysts.

[object Object]
Preview
4.0
12-01TipRanks
Top Analysts Recommend 3 Best Stocks to Purchase as of December 1, 2025

  • Top Analyst Ratings: Recent updates from top Wall Street analysts highlight three stocks—Kratos Defense, LENZ Therapeutics, and Spyre Therapeutics—that have received Strong Buy ratings, indicating solid upside potential.

  • Kratos Defense (KTOS): The stock, which focuses on military drones and national security technologies, has a Buy rating with a price target of $105, suggesting a potential upside of about 31.70%.

  • LENZ Therapeutics (LENZ): This clinical-stage biotech company, developing eye-drop treatments, maintains a Buy rating with a revised price target of $62, indicating an upside of approximately 85.45%.

  • Spyre Therapeutics (SYRE): Focused on treatments for inflammatory bowel disease, Spyre has been upgraded to a Buy with a price target of $64, suggesting a potential upside of around 88.33%.

[object Object]
Preview
9.0
11-18Yahoo Finance
Spyre Therapeutics (SYRE) Reports Encouraging Outcomes from Phase 1 Trial of SPY003

  • Positive Trial Results: Spyre Therapeutics, Inc. announced promising interim Phase 1 results for its drug SPY003, a half-life extended Anti-IL-23 antibody, showing a half-life of approximately 85 days and a favorable safety profile in trials for inflammatory bowel disease and rheumatic diseases.

  • Analyst Rating and Price Target: Julian Harrison of BTIG maintained a Buy rating for Spyre Therapeutics with a $70 price target, highlighting the drug's extended half-life as a significant advancement for less frequent dosing in combination therapies.

  • Financial Position: The company is well-positioned financially, with enough cash to fund operations until the second half of 2028, which supports its ongoing development of antibody-based therapies.

  • Investment Considerations: While Spyre Therapeutics shows potential as an investment, the article suggests that certain AI stocks may offer greater upside potential and lower downside risk, encouraging readers to explore other investment opportunities.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Spyre Therapeutics Inc (SYRE) stock price today?

The current price of SYRE is 33.51 USD — it has increased 4.07 % in the last trading day.

arrow icon

What is Spyre Therapeutics Inc (SYRE)'s business?

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in creating inflammatory bowel disease (IBD) and other immune-mediated disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.

arrow icon

What is the price predicton of SYRE Stock?

Wall Street analysts forecast SYRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SYRE is 54.00 USD with a low forecast of 43.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Spyre Therapeutics Inc (SYRE)'s revenue for the last quarter?

Spyre Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Spyre Therapeutics Inc (SYRE)'s earnings per share (EPS) for the last quarter?

Spyre Therapeutics Inc. EPS for the last quarter amounts to -0.19 USD, decreased -86.03 % YoY.

arrow icon

What changes have occurred in the market's expectations for Spyre Therapeutics Inc (SYRE)'s fundamentals?

The market is revising No Change the revenue expectations for Spyre Therapeutics, Inc. (SYRE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 97.12%.
arrow icon

How many employees does Spyre Therapeutics Inc (SYRE). have?

Spyre Therapeutics Inc (SYRE) has 65 emplpoyees as of December 05 2025.

arrow icon

What is Spyre Therapeutics Inc (SYRE) market cap?

Today SYRE has the market capitalization of 2.60B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free